B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Bioton SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bioton SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioton SA
WSE:BIO
Cash from Financing Activities
-zł15.4m
CAGR 3-Years
-16%
CAGR 5-Years
5%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Cash from Financing Activities
-zł51.8m
CAGR 3-Years
N/A
CAGR 5-Years
-90%
CAGR 10-Years
N/A
R
Read Gene SA
WSE:RDG
Cash from Financing Activities
-zł401.4k
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Cash from Financing Activities
zł9.5k
CAGR 3-Years
-76%
CAGR 5-Years
-61%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Cash from Financing Activities
zł27.4m
CAGR 3-Years
155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Cash from Financing Activities
zł57m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
12%
No Stocks Found

Bioton SA
Glance View

Market Cap
241.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
2.83 PLN
Undervaluation 1%
Intrinsic Value
Price
B

See Also

What is Bioton SA's Cash from Financing Activities?
Cash from Financing Activities
-15.4m PLN

Based on the financial report for Sep 30, 2024, Bioton SA's Cash from Financing Activities amounts to -15.4m PLN.

What is Bioton SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
5%

Over the last year, the Cash from Financing Activities growth was 12%. The average annual Cash from Financing Activities growth rates for Bioton SA have been -16% over the past three years , 5% over the past five years .

Back to Top